High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction

SIMPLE SUMMARY: Afatinib is used to treat non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation as a second-generation EGFR-tyrosine kinase inhibitor (TKI). We examined the relationship between the trough plasma concentrations of afatinib and adverse effects,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Takahashi, Takayuki, Terazono, Hideyuki, Suetsugu, Takayuki, Sugawara, Hideki, Arima, Junko, Nitta, Mina, Tanabe, Toru, Okutsu, Kayu, Ikeda, Ryuji, Mizuno, Keiko, Inoue, Hiromasa, Takeda, Yasuo
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8305619/
https://ncbi.nlm.nih.gov/pubmed/34298637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13143425
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados